A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

NCT04145115 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

NIH

Sponsor class

Conditions

Astrocytoma, IDH-Mutant, Grade 4
Diffuse Glioma
Glioblastoma, IDH-Wildtype
Secondary Glioblastoma

Interventions

BIOLOGICAL: Ipilimumab
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)